Related Experiment Videos
Multidrug resistance-associated protein (MRP) in haematological malignancies
1Department of Medical Oncology, University Hospital Rotterdam and Rotterdam Cancer Institute, The Netherlands.
Abstract:
The presence of multidrug resistant cells, either acquired or de novo, severely limits treatment outcome in haematological malignancies. Although expression of the Mr 170,000 P-glycoprotein drug pump is likely to play a role in multidrug resistance (MDR) in haematological malignancies, it is now evident that other MDR mechanisms may be operational as well in leukaemias, lymphomas, and multiple myeloma. We determined the expression of a newly recognised drug resistance gene, the Multidrug Resistance-associated Protein (MRP) gene, in peripheral blood cells from healthy volunteers and from patients with haematological malignancies. Expression of MRP mRNA and its Mr 190,000 glycoprotein were estimated by RNase protection assay and immunocytochemistry, respectively. MRP appeared to be ubiquitously expressed at low levels in all nonmalignant haemopoietic cell types. However, some leukaemias showed elevated levels of MRP, probably due to transcriptional activation or increased mRNA stability. High to very high MRP expression levels were frequently found in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Acute myelocytic leukemia often exhibited low but occasionally high MRP expression levels, while in the other acute and chronic leukaemias, lymphomas, and multiple myeloma, predominantly low, basal levels of MRP were found. We conclude that hyperexpression of MRP is observed in leukaemias, and that further studies are needed to assess the clinical relevance of MRP.
Insights
Multidrug Resistance-associated Protein (MRP) is expressed in healthy blood cells but can be overexpressed in certain leukemias, potentially impacting treatment outcomes for blood cancers.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Multidrug resistance (MDR) in hematological malignancies limits treatment efficacy.
- While P-glycoprotein is implicated, other MDR mechanisms like Multidrug Resistance-associated Protein (MRP) may also be involved.
- Understanding MRP expression is crucial for improving treatment strategies.
Purpose of the Study:
- To determine the expression levels of the Multidrug Resistance-associated Protein (MRP) gene and its protein product.
- To investigate MRP expression in peripheral blood cells of healthy individuals and patients with hematological malignancies.
- To explore the potential role of MRP in drug resistance in various blood cancers.
Main Methods:
- Quantified MRP mRNA expression using RNase protection assay.
- Assessed MRP glycoprotein levels via immunocytochemistry.
- Analyzed samples from healthy volunteers and patients with leukemia, lymphoma, and multiple myeloma.
Main Results:
- MRP was ubiquitously expressed at low levels in normal hematopoietic cells.
- Elevated MRP mRNA and protein levels were observed in some leukemias, particularly chronic lymphocytic leukemia and prolymphocytic leukemia.
- Acute myelocytic leukemia showed variable MRP expression, while other malignancies displayed predominantly low levels.
Conclusions:
- Hyperexpression of MRP is a notable finding in certain leukemias.
- Further research is required to elucidate the clinical significance of MRP in hematological malignancies.
- MRP may represent a therapeutic target or a biomarker for drug resistance.